Product Description
Vunakizumab (®) is a subcutaneous (SC) recombinant anti-interleukin (IL)-17A humanized monoclonal IgG1/κ antibody being developed by Suzhou Suncadia Biopharmaceutical Co., Ltd (a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd) for the systemic treatment of autoimmune diseases related to the IL-17 pathway, including psoriasis, ankylosing spondylitis and psoriatic arthritis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/39497021/)
Mechanisms of Action: IL17A Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Jiangsu Hengrui Medicine Co
Company Location: Asia Pacific
Company Founding Year: 1970
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Arthritis, Psoriatic|Axial Spondyloarthritis|Psoriasis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06860750 |
SHR-1314-306 | P3 |
Recruiting |
Axial Spondyloarthritis |
2028-02-01 |
20% |
2025-06-24 |
Primary Completion Date|Primary Endpoints |
NCT06833307 |
SHR-1314-307 | P3 |
Not yet recruiting |
Psoriasis |
2026-07-01 |
19% |
2025-02-19 |
Primary Endpoints |
NCT06640257 |
SHR-1314-308 | P3 |
Recruiting |
Arthritis, Psoriatic |
2026-04-30 |
29% |
2024-11-13 |
Primary Endpoints |
NCT06182384 |
SHR-1314-106 | P1 |
Completed |
Psoriasis |
2024-05-13 |
50% |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05055934 |
SHR-1314-204 | P2 |
Completed |
Arthritis, Psoriatic |
2024-06-05 |
40% |
2024-12-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20233963 |
CTR20233963 | P1 |
Completed |
Psoriasis |
2024-05-13 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20212347 |
CTR20212347 | P2 |
Completed |
Arthritis, Psoriatic |
2024-06-05 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|